As a trusted leader in the immunotherapy field, the Society for Immunotherapy of Cancer (SITC) collaborates with other groups to contribute toward high-quality educational programming on tumor immunology and cancer immunotherapy.
Through these educational partnerships, SITC is able to bring high quality, timely cancer immunotherapy information to learners around the world from a variety of backgrounds including scientists, academicians, researchers, clinicians, government representatives and industry leaders.
SITC offers various levels of support for the programs below, such as sharing information about unique programs, providing expert speakers to enhance programming and organizing immunotherapy sessions at relevant association meetings.
If you'd like to get in touch with the society to discuss Collaborative Education Programs, please email the SITC Live Education Department at Education@sitcancer.org.
Join SITC members, Drs. Vincenzo Bronte, Lorenzo Galluzzi and Jérôme Galon, for the Primer on Cancer Immunology and Immunotherapy at the International Conference on Immunotherapy Radiotherapy Combinations Sept. 20–22 in Paris. Attention SITC members! ...
This two day program is divided into a lectures series presented by world class scientists in the field of immuno-oncology, and a hands-on workshop laboratory to explore the optimization and troubleshooting of Opal staining, multispectral image acquisition ...
Currently scfvs, antibody-derived single chain variable fragment based CAR to target CD19 antigen is the most common CAR strategy clinically used. But based on the cited article, tumor cells can be targeted also through use of non-antibody based approahes.This ...
Dear Dr. Ramakrishna, Below please find a short summary of immunotherapies targeting CD123, CD33. All can be found on clinicaltrials.gov. I have heard that the City of Hope (COH) CAR T cells anti-CD123 study is showing early promise, but I have no ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org